Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study.

Gold R, Comi G, Palace J, Siever A, Gottschalk R, Bijarnia M, von Rosenstiel P, Tomic D, Kappos L; FIRST Study Investigators..

J Neurol. 2014 Feb;261(2):267-76. doi: 10.1007/s00415-013-7115-8. Epub 2013 Nov 13.

2.

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD.

Lancet Neurol. 2014 Jun;13(6):545-56. doi: 10.1016/S1474-4422(14)70049-3. Epub 2014 Mar 28. Erratum in: Lancet Neurol. 2013 Jun;13(6):536.

PMID:
24685276
3.

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, Burtin P; FREEDOMS Study Group..

N Engl J Med. 2010 Feb 4;362(5):387-401. doi: 10.1056/NEJMoa0909494. Epub 2010 Jan 20.

4.

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, Tiel-Wilck K, de Vera A, Jin J, Stites T, Wu S, Aradhye S, Kappos L; TRANSFORMS Study Group..

N Engl J Med. 2010 Feb 4;362(5):402-15. doi: 10.1056/NEJMoa0907839. Epub 2010 Jan 20.

5.

First-dose effects of fingolimod after switching from injectable therapies in the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study in relapsing multiple sclerosis.

Hughes B, Cascione M, Freedman MS, Agius M, Kantor D, Gudesblatt M, Goldstick LP, Agashivala N, Schofield L, McCague K, Hashmonay R, Barbato L; EPOC study investigators..

Mult Scler Relat Disord. 2014 Sep;3(5):620-8. doi: 10.1016/j.msard.2014.06.006. Epub 2014 Jul 3.

PMID:
26265274
6.

Vagomimetic effects of fingolimod: physiology and clinical implications.

Vanoli E, Pentimalli F, Botto G.

CNS Neurosci Ther. 2014 Jun;20(6):496-502. doi: 10.1111/cns.12283. Review.

7.

Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.

Devonshire V, Havrdova E, Radue EW, O'Connor P, Zhang-Auberson L, Agoropoulou C, Häring DA, Francis G, Kappos L; FREEDOMS study group..

Lancet Neurol. 2012 May;11(5):420-8. doi: 10.1016/S1474-4422(12)70056-X. Epub 2012 Apr 10. Erratum in: Lancet Neurol. 2012 Aug;11(8):658.

PMID:
22494956
8.

[Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].

Széplaki G, Merkely B.

Ideggyogy Sz. 2012 Nov 30;65(11-12):369-76. Review. Hungarian.

PMID:
23289171
9.

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.

Laroni A, Brogi D, Morra VB, Guidi L, Pozzilli C, Comi G, Lugaresi A, Turrini R, Raimondi D, Uccelli A, Mancardi GL; EAP Investigators..

BMC Neurol. 2014 Apr 1;14:65. doi: 10.1186/1471-2377-14-65.

10.

A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis.

Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, Nagato K, Tang D, Zhang-Auberson L, Kira J.

Mult Scler. 2012 Sep;18(9):1269-77. doi: 10.1177/1352458511435984. Epub 2012 Feb 21.

PMID:
22354739
11.

Oral fingolimod (FTY720) for relapsing multiple sclerosis.

Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, Haas T, Korn AA, Karlsson G, Radue EW; FTY720 D2201 Study Group..

N Engl J Med. 2006 Sep 14;355(11):1124-40.

12.

Fingolimod in a patient with Wolff-Parkinson-White syndrome.

Huys AC, Lalive PH, Sekoranja L.

Mult Scler. 2014 Apr;20(5):636-7. doi: 10.1177/1352458513499422. Epub 2013 Jul 29. No abstract available.

PMID:
23897641
13.

Real-world use of fingolimod in patients with relapsing remitting multiple sclerosis: a retrospective study using the national multiple sclerosis registry in Kuwait.

Al-Hashel J, Ahmed SF, Behbehani R, Alroughani R.

CNS Drugs. 2014 Sep;28(9):817-24. doi: 10.1007/s40263-014-0185-z.

PMID:
25011422
14.

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, Montalban X, Pelletier J, Stites T, Wu S, Holdbrook F, Zhang-Auberson L, Francis G, Cohen JA; TRANSFORMS Study Group..

Lancet Neurol. 2011 Jun;10(6):520-9. doi: 10.1016/S1474-4422(11)70099-0. Epub 2011 May 13.

PMID:
21571593
15.

Fingolimod: a review of its use in the management of relapsing-remitting multiple sclerosis.

Scott LJ.

CNS Drugs. 2011 Aug;25(8):673-98. doi: 10.2165/11207350-000000000-00000. Review.

PMID:
21790210
16.

Fingolimod: a review of its use in relapsing-remitting multiple sclerosis.

Sanford M.

Drugs. 2014 Aug;74(12):1411-33. doi: 10.1007/s40265-014-0264-y. Review.

PMID:
25063048
17.

Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.

Kira J, Itoyama Y, Kikuchi S, Hao Q, Kurosawa T, Nagato K, Tsumiyama I, von Rosenstiel P, Zhang-Auberson L, Saida T.

BMC Neurol. 2014 Jan 29;14:21. doi: 10.1186/1471-2377-14-21.

18.

Electrocardiographic assessments and cardiac events after fingolimod first dose - a comprehensive monitoring study.

Limmroth V, Ziemssen T, Lang M, Richter S, Wagner B, Haas J, Schmidt S, Gerbershagen K, Lassek C, Klotz L, Hoffmann O, Albert C, Schuh K, Baier-Ebert M, Wendt G, Schieb H, Hoyer S, Dechend R, Haverkamp W.

BMC Neurol. 2017 Jan 18;17(1):11. doi: 10.1186/s12883-016-0789-7.

19.

Fingolimod-induced atrioventricular conduction defects in a young lady with multiple sclerosis--insights into possible drug mechanism.

Voon V, Saiva L, O'Kelly S, Keane D.

Eur J Clin Pharmacol. 2014 Mar;70(3):373-5. doi: 10.1007/s00228-013-1620-7. Epub 2013 Dec 6. No abstract available.

PMID:
24309839
20.

Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial.

Kappos L, O'Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, Ritter S, Schlosshauer R, von Rosenstiel P, Zhang-Auberson L, Francis G.

Neurology. 2015 Apr 14;84(15):1582-91. doi: 10.1212/WNL.0000000000001462. Epub 2015 Mar 20.

Supplemental Content

Support Center